Skip to main content

Alland Leila's Form 4 filing

PMV Pharmaceuticals, Inc. (PMVP) · filed Sep 10, 2021

Accession no.
0001209191-21-055438
Filed
Sep 10, 2021
Trade date
Sep 9, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.02K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Alland LeilaCIK 0001825216Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 9, 2021Common StockMOption exerciseAcquired+100$3.90+$390100Direct
Sep 9, 2021Common StockSSaleDisposed−100$30.25−$3,0250Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 9, 2021Common StockMOption exerciseDisposed−100$0.00$0353,850Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)